nodes	percent_of_prediction	percent_of_DWPC	metapath
Rufinamide—CYP2E1—Mitoxantrone—lymphatic system cancer	0.135	0.359	CbGbCtD
Rufinamide—Oligomenorrhoea—Mechlorethamine—lymphatic system cancer	0.0859	0.138	CcSEcCtD
Rufinamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0594	0.158	CbGbCtD
Rufinamide—CYP3A4—Teniposide—lymphatic system cancer	0.0586	0.155	CbGbCtD
Rufinamide—ALB—Methotrexate—lymphatic system cancer	0.0544	0.144	CbGbCtD
Rufinamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.041	0.109	CbGbCtD
Rufinamide—CYP3A4—Vincristine—lymphatic system cancer	0.0282	0.0748	CbGbCtD
Rufinamide—Nystagmus—Vincristine—lymphatic system cancer	0.00736	0.0118	CcSEcCtD
Rufinamide—Aggression—Bleomycin—lymphatic system cancer	0.00718	0.0115	CcSEcCtD
Rufinamide—Contusion—Mitoxantrone—lymphatic system cancer	0.00587	0.00942	CcSEcCtD
Rufinamide—Neutropenia—Teniposide—lymphatic system cancer	0.00574	0.00922	CcSEcCtD
Rufinamide—Gait disturbance—Carmustine—lymphatic system cancer	0.00564	0.00906	CcSEcCtD
Rufinamide—Coordination abnormal—Carmustine—lymphatic system cancer	0.00561	0.009	CcSEcCtD
Rufinamide—Gait disturbance—Vincristine—lymphatic system cancer	0.00539	0.00864	CcSEcCtD
Rufinamide—Urinary incontinence—Carmustine—lymphatic system cancer	0.00532	0.00853	CcSEcCtD
Rufinamide—Vertigo—Mechlorethamine—lymphatic system cancer	0.00522	0.00837	CcSEcCtD
Rufinamide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0052	0.00834	CcSEcCtD
Rufinamide—Bronchitis—Fludarabine—lymphatic system cancer	0.00519	0.00833	CcSEcCtD
Rufinamide—Dysuria—Fludarabine—lymphatic system cancer	0.00505	0.0081	CcSEcCtD
Rufinamide—Neutropenia—Fludarabine—lymphatic system cancer	0.00505	0.0081	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00491	0.00788	CcSEcCtD
Rufinamide—Pneumonia—Fludarabine—lymphatic system cancer	0.00484	0.00777	CcSEcCtD
Rufinamide—Urine output increased—Vincristine—lymphatic system cancer	0.00475	0.00763	CcSEcCtD
Rufinamide—Infection—Mechlorethamine—lymphatic system cancer	0.00471	0.00755	CcSEcCtD
Rufinamide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00464	0.00744	CcSEcCtD
Rufinamide—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0046	0.00739	CcSEcCtD
Rufinamide—Haematuria—Fludarabine—lymphatic system cancer	0.00459	0.00737	CcSEcCtD
Rufinamide—Epistaxis—Fludarabine—lymphatic system cancer	0.00454	0.00729	CcSEcCtD
Rufinamide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00452	0.00725	CcSEcCtD
Rufinamide—Sinusitis—Fludarabine—lymphatic system cancer	0.00452	0.00725	CcSEcCtD
Rufinamide—Polyuria—Vincristine—lymphatic system cancer	0.00435	0.00697	CcSEcCtD
Rufinamide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00412	0.00661	CcSEcCtD
Rufinamide—Diplopia—Carmustine—lymphatic system cancer	0.004	0.00642	CcSEcCtD
Rufinamide—Anaemia—Teniposide—lymphatic system cancer	0.00396	0.00635	CcSEcCtD
Rufinamide—Agitation—Teniposide—lymphatic system cancer	0.00393	0.00631	CcSEcCtD
Rufinamide—Leukopenia—Teniposide—lymphatic system cancer	0.00383	0.00615	CcSEcCtD
Rufinamide—Malnutrition—Fludarabine—lymphatic system cancer	0.00376	0.00604	CcSEcCtD
Rufinamide—Ataxia—Carmustine—lymphatic system cancer	0.00376	0.00603	CcSEcCtD
Rufinamide—Ataxia—Vincristine—lymphatic system cancer	0.00359	0.00576	CcSEcCtD
Rufinamide—Weight decreased—Bleomycin—lymphatic system cancer	0.00358	0.00575	CcSEcCtD
Rufinamide—Pneumonia—Bleomycin—lymphatic system cancer	0.00355	0.0057	CcSEcCtD
Rufinamide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00349	0.0056	CcSEcCtD
Rufinamide—Anaemia—Fludarabine—lymphatic system cancer	0.00348	0.00558	CcSEcCtD
Rufinamide—Infection—Teniposide—lymphatic system cancer	0.00347	0.00557	CcSEcCtD
Rufinamide—Agitation—Fludarabine—lymphatic system cancer	0.00346	0.00555	CcSEcCtD
Rufinamide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00342	0.00549	CcSEcCtD
Rufinamide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00339	0.00545	CcSEcCtD
Rufinamide—Leukopenia—Fludarabine—lymphatic system cancer	0.00337	0.0054	CcSEcCtD
Rufinamide—Haematuria—Bleomycin—lymphatic system cancer	0.00337	0.0054	CcSEcCtD
Rufinamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00335	0.00538	CcSEcCtD
Rufinamide—Anorexia—Teniposide—lymphatic system cancer	0.00333	0.00534	CcSEcCtD
Rufinamide—Convulsion—Fludarabine—lymphatic system cancer	0.00326	0.00523	CcSEcCtD
Rufinamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00324	0.0052	CcSEcCtD
Rufinamide—Neutropenia—Carmustine—lymphatic system cancer	0.00323	0.00518	CcSEcCtD
Rufinamide—Pneumonia—Carmustine—lymphatic system cancer	0.0031	0.00497	CcSEcCtD
Rufinamide—Dysuria—Vincristine—lymphatic system cancer	0.00308	0.00495	CcSEcCtD
Rufinamide—Neutropenia—Vincristine—lymphatic system cancer	0.00308	0.00495	CcSEcCtD
Rufinamide—Infection—Fludarabine—lymphatic system cancer	0.00305	0.00489	CcSEcCtD
Rufinamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00304	0.00487	CcSEcCtD
Rufinamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00301	0.00483	CcSEcCtD
Rufinamide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00301	0.00483	CcSEcCtD
Rufinamide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00301	0.00482	CcSEcCtD
Rufinamide—Neutropenia—Mitoxantrone—lymphatic system cancer	0.003	0.00482	CcSEcCtD
Rufinamide—Rash—Mechlorethamine—lymphatic system cancer	0.00299	0.00479	CcSEcCtD
Rufinamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00298	0.00479	CcSEcCtD
Rufinamide—Weight decreased—Vincristine—lymphatic system cancer	0.00298	0.00479	CcSEcCtD
Rufinamide—Pneumonia—Vincristine—lymphatic system cancer	0.00296	0.00475	CcSEcCtD
Rufinamide—Anorexia—Fludarabine—lymphatic system cancer	0.00293	0.0047	CcSEcCtD
Rufinamide—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00291	0.00466	CcSEcCtD
Rufinamide—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00288	0.00462	CcSEcCtD
Rufinamide—Bone disorder—Methotrexate—lymphatic system cancer	0.00282	0.00453	CcSEcCtD
Rufinamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00281	0.00452	CcSEcCtD
Rufinamide—Haematuria—Mitoxantrone—lymphatic system cancer	0.00273	0.00438	CcSEcCtD
Rufinamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.0027	0.00434	CcSEcCtD
Rufinamide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00269	0.00431	CcSEcCtD
Rufinamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00267	0.00428	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00265	0.00425	CcSEcCtD
Rufinamide—Fatigue—Fludarabine—lymphatic system cancer	0.00265	0.00425	CcSEcCtD
Rufinamide—Constipation—Fludarabine—lymphatic system cancer	0.00263	0.00421	CcSEcCtD
Rufinamide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00261	0.00418	CcSEcCtD
Rufinamide—Urethral disorder—Vincristine—lymphatic system cancer	0.00259	0.00415	CcSEcCtD
Rufinamide—Eye disorder—Carmustine—lymphatic system cancer	0.00258	0.00415	CcSEcCtD
Rufinamide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00258	0.00414	CcSEcCtD
Rufinamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00257	0.00413	CcSEcCtD
Rufinamide—Anaemia—Bleomycin—lymphatic system cancer	0.00255	0.00409	CcSEcCtD
Rufinamide—Asthenia—Teniposide—lymphatic system cancer	0.00251	0.00402	CcSEcCtD
Rufinamide—Pruritus—Teniposide—lymphatic system cancer	0.00247	0.00397	CcSEcCtD
Rufinamide—Leukopenia—Bleomycin—lymphatic system cancer	0.00247	0.00396	CcSEcCtD
Rufinamide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00245	0.00393	CcSEcCtD
Rufinamide—Mental disorder—Carmustine—lymphatic system cancer	0.00242	0.00389	CcSEcCtD
Rufinamide—Malnutrition—Carmustine—lymphatic system cancer	0.00241	0.00386	CcSEcCtD
Rufinamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00239	0.00384	CcSEcCtD
Rufinamide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00238	0.00382	CcSEcCtD
Rufinamide—Back pain—Carmustine—lymphatic system cancer	0.00233	0.00374	CcSEcCtD
Rufinamide—Mental disorder—Vincristine—lymphatic system cancer	0.00231	0.00371	CcSEcCtD
Rufinamide—Urine output increased—Methotrexate—lymphatic system cancer	0.00231	0.0037	CcSEcCtD
Rufinamide—Vision blurred—Carmustine—lymphatic system cancer	0.00227	0.00364	CcSEcCtD
Rufinamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00226	0.00363	CcSEcCtD
Rufinamide—Tremor—Carmustine—lymphatic system cancer	0.00226	0.00362	CcSEcCtD
Rufinamide—Infection—Bleomycin—lymphatic system cancer	0.00224	0.00359	CcSEcCtD
Rufinamide—Anaemia—Carmustine—lymphatic system cancer	0.00223	0.00357	CcSEcCtD
Rufinamide—Back pain—Vincristine—lymphatic system cancer	0.00222	0.00357	CcSEcCtD
Rufinamide—Vomiting—Teniposide—lymphatic system cancer	0.00222	0.00356	CcSEcCtD
Rufinamide—Agitation—Carmustine—lymphatic system cancer	0.00221	0.00355	CcSEcCtD
Rufinamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0022	0.00354	CcSEcCtD
Rufinamide—Asthenia—Fludarabine—lymphatic system cancer	0.0022	0.00353	CcSEcCtD
Rufinamide—Rash—Teniposide—lymphatic system cancer	0.0022	0.00353	CcSEcCtD
Rufinamide—Dermatitis—Teniposide—lymphatic system cancer	0.0022	0.00353	CcSEcCtD
Rufinamide—Headache—Teniposide—lymphatic system cancer	0.00219	0.00351	CcSEcCtD
Rufinamide—Pruritus—Fludarabine—lymphatic system cancer	0.00217	0.00349	CcSEcCtD
Rufinamide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00217	0.00348	CcSEcCtD
Rufinamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00217	0.00347	CcSEcCtD
Rufinamide—Leukopenia—Carmustine—lymphatic system cancer	0.00216	0.00346	CcSEcCtD
Rufinamide—Anorexia—Bleomycin—lymphatic system cancer	0.00215	0.00344	CcSEcCtD
Rufinamide—Anaemia—Vincristine—lymphatic system cancer	0.00212	0.00341	CcSEcCtD
Rufinamide—Agitation—Vincristine—lymphatic system cancer	0.00211	0.00339	CcSEcCtD
Rufinamide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00211	0.00339	CcSEcCtD
Rufinamide—Polyuria—Methotrexate—lymphatic system cancer	0.00211	0.00338	CcSEcCtD
Rufinamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.0021	0.00337	CcSEcCtD
Rufinamide—Convulsion—Carmustine—lymphatic system cancer	0.00209	0.00335	CcSEcCtD
Rufinamide—Nausea—Teniposide—lymphatic system cancer	0.00207	0.00333	CcSEcCtD
Rufinamide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00207	0.00332	CcSEcCtD
Rufinamide—Vertigo—Vincristine—lymphatic system cancer	0.00206	0.00331	CcSEcCtD
Rufinamide—Leukopenia—Vincristine—lymphatic system cancer	0.00206	0.0033	CcSEcCtD
Rufinamide—Anxiety—Carmustine—lymphatic system cancer	0.00204	0.00328	CcSEcCtD
Rufinamide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.002	0.00322	CcSEcCtD
Rufinamide—Convulsion—Vincristine—lymphatic system cancer	0.00199	0.0032	CcSEcCtD
Rufinamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00196	0.00314	CcSEcCtD
Rufinamide—Infection—Carmustine—lymphatic system cancer	0.00195	0.00313	CcSEcCtD
Rufinamide—Vomiting—Fludarabine—lymphatic system cancer	0.00195	0.00313	CcSEcCtD
Rufinamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00194	0.00311	CcSEcCtD
Rufinamide—Rash—Fludarabine—lymphatic system cancer	0.00194	0.00311	CcSEcCtD
Rufinamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00193	0.0031	CcSEcCtD
Rufinamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00192	0.00309	CcSEcCtD
Rufinamide—Headache—Fludarabine—lymphatic system cancer	0.00192	0.00309	CcSEcCtD
Rufinamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.0019	0.00305	CcSEcCtD
Rufinamide—Anorexia—Carmustine—lymphatic system cancer	0.00187	0.00301	CcSEcCtD
Rufinamide—Infection—Vincristine—lymphatic system cancer	0.00186	0.00299	CcSEcCtD
Rufinamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00184	0.00295	CcSEcCtD
Rufinamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00184	0.00295	CcSEcCtD
Rufinamide—Nausea—Fludarabine—lymphatic system cancer	0.00182	0.00293	CcSEcCtD
Rufinamide—Infection—Mitoxantrone—lymphatic system cancer	0.00181	0.00291	CcSEcCtD
Rufinamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00179	0.00287	CcSEcCtD
Rufinamide—Anorexia—Vincristine—lymphatic system cancer	0.00179	0.00287	CcSEcCtD
Rufinamide—Insomnia—Carmustine—lymphatic system cancer	0.00178	0.00285	CcSEcCtD
Rufinamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00177	0.00285	CcSEcCtD
Rufinamide—Somnolence—Carmustine—lymphatic system cancer	0.00175	0.0028	CcSEcCtD
Rufinamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00174	0.00279	CcSEcCtD
Rufinamide—Ataxia—Methotrexate—lymphatic system cancer	0.00174	0.00279	CcSEcCtD
Rufinamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00171	0.00274	CcSEcCtD
Rufinamide—Insomnia—Vincristine—lymphatic system cancer	0.0017	0.00272	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0017	0.00272	CcSEcCtD
Rufinamide—Constipation—Carmustine—lymphatic system cancer	0.00168	0.0027	CcSEcCtD
Rufinamide—Breast disorder—Methotrexate—lymphatic system cancer	0.00167	0.00269	CcSEcCtD
Rufinamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00166	0.00266	CcSEcCtD
Rufinamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00163	0.00262	CcSEcCtD
Rufinamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00162	0.00261	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00162	0.0026	CcSEcCtD
Rufinamide—Fatigue—Vincristine—lymphatic system cancer	0.00162	0.0026	CcSEcCtD
Rufinamide—Asthenia—Bleomycin—lymphatic system cancer	0.00162	0.00259	CcSEcCtD
Rufinamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00161	0.00258	CcSEcCtD
Rufinamide—Constipation—Vincristine—lymphatic system cancer	0.0016	0.00257	CcSEcCtD
Rufinamide—Pruritus—Bleomycin—lymphatic system cancer	0.00159	0.00256	CcSEcCtD
Rufinamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00159	0.00255	CcSEcCtD
Rufinamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00157	0.00253	CcSEcCtD
Rufinamide—Constipation—Mitoxantrone—lymphatic system cancer	0.00156	0.00251	CcSEcCtD
Rufinamide—Dysuria—Methotrexate—lymphatic system cancer	0.0015	0.0024	CcSEcCtD
Rufinamide—Neutropenia—Methotrexate—lymphatic system cancer	0.0015	0.0024	CcSEcCtD
Rufinamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00145	0.00232	CcSEcCtD
Rufinamide—Pneumonia—Methotrexate—lymphatic system cancer	0.00144	0.0023	CcSEcCtD
Rufinamide—Vomiting—Bleomycin—lymphatic system cancer	0.00143	0.0023	CcSEcCtD
Rufinamide—Infestation NOS—Methotrexate—lymphatic system cancer	0.00143	0.00229	CcSEcCtD
Rufinamide—Infestation—Methotrexate—lymphatic system cancer	0.00143	0.00229	CcSEcCtD
Rufinamide—Rash—Bleomycin—lymphatic system cancer	0.00142	0.00228	CcSEcCtD
Rufinamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00142	0.00228	CcSEcCtD
Rufinamide—Asthenia—Carmustine—lymphatic system cancer	0.00141	0.00226	CcSEcCtD
Rufinamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00138	0.00222	CcSEcCtD
Rufinamide—Haematuria—Methotrexate—lymphatic system cancer	0.00136	0.00218	CcSEcCtD
Rufinamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00135	0.00217	CcSEcCtD
Rufinamide—Epistaxis—Methotrexate—lymphatic system cancer	0.00135	0.00216	CcSEcCtD
Rufinamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00135	0.00216	CcSEcCtD
Rufinamide—Asthenia—Vincristine—lymphatic system cancer	0.00135	0.00216	CcSEcCtD
Rufinamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00134	0.00216	CcSEcCtD
Rufinamide—Nausea—Bleomycin—lymphatic system cancer	0.00134	0.00215	CcSEcCtD
Rufinamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00131	0.0021	CcSEcCtD
Rufinamide—Dizziness—Carmustine—lymphatic system cancer	0.0013	0.00209	CcSEcCtD
Rufinamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00128	0.00206	CcSEcCtD
Rufinamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00127	0.00203	CcSEcCtD
Rufinamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00126	0.00202	CcSEcCtD
Rufinamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00125	0.00201	CcSEcCtD
Rufinamide—Vomiting—Carmustine—lymphatic system cancer	0.00125	0.002	CcSEcCtD
Rufinamide—Dizziness—Vincristine—lymphatic system cancer	0.00124	0.00199	CcSEcCtD
Rufinamide—Rash—Carmustine—lymphatic system cancer	0.00124	0.00199	CcSEcCtD
Rufinamide—Dermatitis—Carmustine—lymphatic system cancer	0.00124	0.00199	CcSEcCtD
Rufinamide—Headache—Carmustine—lymphatic system cancer	0.00123	0.00198	CcSEcCtD
Rufinamide—Eye disorder—Methotrexate—lymphatic system cancer	0.0012	0.00192	CcSEcCtD
Rufinamide—Vomiting—Vincristine—lymphatic system cancer	0.00119	0.00191	CcSEcCtD
Rufinamide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00119	0.00191	CcSEcCtD
Rufinamide—Rash—Vincristine—lymphatic system cancer	0.00118	0.0019	CcSEcCtD
Rufinamide—Dermatitis—Vincristine—lymphatic system cancer	0.00118	0.0019	CcSEcCtD
Rufinamide—Headache—Vincristine—lymphatic system cancer	0.00118	0.00189	CcSEcCtD
Rufinamide—Nausea—Carmustine—lymphatic system cancer	0.00117	0.00187	CcSEcCtD
Rufinamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00116	0.00186	CcSEcCtD
Rufinamide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00116	0.00186	CcSEcCtD
Rufinamide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00115	0.00185	CcSEcCtD
Rufinamide—Rash—Mitoxantrone—lymphatic system cancer	0.00115	0.00185	CcSEcCtD
Rufinamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00115	0.00185	CcSEcCtD
Rufinamide—Headache—Mitoxantrone—lymphatic system cancer	0.00114	0.00184	CcSEcCtD
Rufinamide—Mental disorder—Methotrexate—lymphatic system cancer	0.00112	0.0018	CcSEcCtD
Rufinamide—Malnutrition—Methotrexate—lymphatic system cancer	0.00112	0.00179	CcSEcCtD
Rufinamide—Nausea—Vincristine—lymphatic system cancer	0.00111	0.00179	CcSEcCtD
Rufinamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00109	0.00174	CcSEcCtD
Rufinamide—Back pain—Methotrexate—lymphatic system cancer	0.00108	0.00173	CcSEcCtD
Rufinamide—Vision blurred—Methotrexate—lymphatic system cancer	0.00105	0.00169	CcSEcCtD
Rufinamide—Anaemia—Methotrexate—lymphatic system cancer	0.00103	0.00165	CcSEcCtD
Rufinamide—Vertigo—Methotrexate—lymphatic system cancer	0.001	0.00161	CcSEcCtD
Rufinamide—Leukopenia—Methotrexate—lymphatic system cancer	0.000998	0.0016	CcSEcCtD
Rufinamide—Convulsion—Methotrexate—lymphatic system cancer	0.000966	0.00155	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000943	0.00151	CcSEcCtD
Rufinamide—Infection—Methotrexate—lymphatic system cancer	0.000904	0.00145	CcSEcCtD
Rufinamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000893	0.00143	CcSEcCtD
Rufinamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000891	0.00143	CcSEcCtD
Rufinamide—Skin disorder—Methotrexate—lymphatic system cancer	0.000884	0.00142	CcSEcCtD
Rufinamide—Anorexia—Methotrexate—lymphatic system cancer	0.000868	0.00139	CcSEcCtD
Rufinamide—Insomnia—Methotrexate—lymphatic system cancer	0.000823	0.00132	CcSEcCtD
Rufinamide—Somnolence—Methotrexate—lymphatic system cancer	0.000809	0.0013	CcSEcCtD
Rufinamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000801	0.00129	CcSEcCtD
Rufinamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000791	0.00127	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000786	0.00126	CcSEcCtD
Rufinamide—Fatigue—Methotrexate—lymphatic system cancer	0.000785	0.00126	CcSEcCtD
Rufinamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000671	0.00108	CcSEcCtD
Rufinamide—Asthenia—Methotrexate—lymphatic system cancer	0.000653	0.00105	CcSEcCtD
Rufinamide—Pruritus—Methotrexate—lymphatic system cancer	0.000644	0.00103	CcSEcCtD
Rufinamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000623	0.000999	CcSEcCtD
Rufinamide—Dizziness—Methotrexate—lymphatic system cancer	0.000602	0.000966	CcSEcCtD
Rufinamide—Vomiting—Methotrexate—lymphatic system cancer	0.000579	0.000929	CcSEcCtD
Rufinamide—Rash—Methotrexate—lymphatic system cancer	0.000574	0.000921	CcSEcCtD
Rufinamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000573	0.00092	CcSEcCtD
Rufinamide—Headache—Methotrexate—lymphatic system cancer	0.00057	0.000915	CcSEcCtD
Rufinamide—Nausea—Methotrexate—lymphatic system cancer	0.000541	0.000868	CcSEcCtD
